BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, July 14, 2026
Home » Blogs » BioWorld MedTech Perspectives » On This Date in History; Michael DeBakey born 1908

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

On This Date in History; Michael DeBakey born 1908

Sep. 7, 2012
By Mark McCarty

The world of cardiology still holds a spot front and center in the realm of medical technology, so it only seems fitting to celebrate the birth of Michael Ellis DeBakey, MD, whose birth on Sept. 7, 1908 was followed by his passing very nearly 100 years later to the day, July 11, 2008.

In the ten decades between those two dates, the physician was published more than a thousand times in medical journals and in bound books. DeBakey’s name would become synonymous with pioneering efforts in circulatory system surgery, but the man who was born Michael Dabaghi in Lake Charles, Louisiana, would come out with his first innovation at the relatively tender age of 23, when according to the Baylor College of Medicine website, DeBakey invented the roller pump, which would collect dust for 20 years before the world realized the role it could play in the heart-lung machine.

DeBakey is also credited with having performed the first carotid artery endarterectomy, which took place in 1953, although the first endarterectomy of any kind had been performed on a femoral artery seven years earlier by Joao Cid dos Santos, MD, whose debut of the procedure is said to have taken place at the University of Lisbon.

What else you ask? DeBakey is credited with having pioneered the use of Dacron grafts, is said to have performed the first patch-graft angioplasty, and was one of the first surgeons to invite film crews into the OR to record a surgical procedure. Those who enjoy the live-action procedures routinely seen at gatherings such as TCT have DeBakey, among others, to thank for the availability of such video access.

Ironically, DeBakey suffered an aortic dissection in 2005, an event that nearly claimed his life. When he died three years later, DeBakey had unfortunately been preceded in death by his first wife and two sons, although his second wife and five other children would survive him.

Among the institutions that would also survive DeBakey’s passing is the Foundation for Biomedical Research, which supports the ethical use of animals in medical testing. Another institution of sorts, the left ventricular bypass pump, was also a product of DeBakey’s med-tech family tree.

Only occasionally is humankind blessed with the gifts of a truly rare talent – dare I say genius? – such as DeBakey’s, but his reputation is also based on longevity. DeBakey’s career spanned the latter years of the Great Depression, a world war, the fall of the Iron Curtain, dozens of congresses and a dozen U.S. presidents. DeBakey is said to have practiced medicine up to the time of his death, a standard of dedication to his craft that eclipses even his brilliance in cardiology.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 13, 2026.
  • Silhouette with keyhole

    FENS 2026: Next-gen biologics take on brain disease

    BioWorld
    Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
  • Wainua autoinjector

    Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

    BioWorld
    News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
  • Modius Spero wearable neuromodulation device

    Neurovalens granted FDA approval for PTSD therapy for US veterans

    BioWorld
    Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
  • NRF2 activators reported in Vailima Peninsula patent

    BioWorld Science
    Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing